PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.

Scope of the Report:

This report studies the PARP (Poly ADP-Ribose Polymerase) Inhibitor market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the PARP (Poly ADP-Ribose Polymerase) Inhibitor market by product type and applications/end industries.

The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of PARP (Poly ADP-Ribose Polymerase) Inhibitor.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Tesaro

Clovis Oncology

AstraZeneca

Abbvie

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Started Phase I

Started Phase II

Started Phase III

Market Segment by Applications, can be divided into

Hospitals

Drug Stores

Online

Table of Contents

1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Overview

1.1 Product Overview and Scope of PARP (Poly ADP-Ribose Polymerase) Inhibitor

1.2 Classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Types

1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Comparison by Types (2017-2023)

1.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Types in 2017

1.2.3 Started Phase I

1.2.4 Started Phase II

1.2.5 Started Phase III

1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Application

1.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Drug Stores

1.3.4 Online

1.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Regions

1.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) PARP (Poly ADP-Ribose Polymerase) Inhibitor Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) PARP (Poly ADP-Ribose Polymerase) Inhibitor Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) PARP (Poly ADP-Ribose Polymerase) Inhibitor Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) PARP (Poly ADP-Ribose Polymerase) Inhibitor Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) PARP (Poly ADP-Ribose Polymerase) Inhibitor Status and Prospect (2013-2023)

1.5 Global Market Size of PARP (Poly ADP-Ribose Polymerase) Inhibitor (2013-2023)

2 Manufacturers Profiles

2.1 Tesaro

2.1.1 Business Overview

2.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, Gross Margin and Market Share (2016-2017)

2.2 Clovis Oncology

2.2.1 Business Overview

2.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, Gross Margin and Market Share (2016-2017)

2.3 AstraZeneca

2.3.1 Business Overview

2.3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, Gross Margin and Market Share (2016-2017)

2.4 Abbvie

2.4.1 Business Overview

2.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Abbvie PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, Gross Margin and Market Share (2016-2017)

3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competition, by Players

3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share

3.2.2 Top 10 PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share

3.3 Market Competition Trend

4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Regions

4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Regions

4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

4.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

4.5 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

5 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries

5.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2013-2018)

5.2 USA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

5.3 Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

5.4 Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

6 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries

6.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2013-2018)

6.2 Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

6.3 UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

6.4 France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

6.5 Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

6.6 Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

7 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries

7.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2013-2018)

7.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

7.3 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

7.4 Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

7.5 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

8 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries

8.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2013-2018)

8.2 Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

8.3 Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

8.4 Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries

9.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2013-2018)

9.2 Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

9.3 UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

9.4 Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

9.5 Nigeria PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

9.6 South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2013-2018)

10 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Type

10.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2013-2018)

10.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Type (2018-2023)

10.3 Started Phase I Revenue Growth Rate (2013-2023)

10.4 Started Phase II Revenue Growth Rate (2013-2023)

10.5 Started Phase III Revenue Growth Rate (2013-2023)

11 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Application

11.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2013-2018)

11.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Drug Stores Revenue Growth (2013-2018)

11.5 Online Revenue Growth (2013-2018)

12 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast (2018-2023)

12.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast (2018-2023)

12.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Regions (2018-2023)

12.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Forecast (2018-2023)

12.4 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Forecast (2018-2023)

12.6 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Picture

Table Product Specifications of PARP (Poly ADP-Ribose Polymerase) Inhibitor

Table Global PARP (Poly ADP-Ribose Po